Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Misoprostol for Bloating and Distension
NCT04768010 · Montefiore Medical Center · EARLY_PHASE1 · withdrawn · last registry update 2023-09-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “After significant delays study was never initiated. No participants enrolled” | – | Registry record, Montefiore Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGER3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-28Also stopped (terminated): University Hospital, Limoges, Dinoprostone + Oxytocine (NCT02888041)
- 2024-08-15Results posted on the registry: Centre Hospitalier Departemental Vendee, Dinoprostone (NCT02649920)
- 2024-08-15Also stopped (terminated): Centre Hospitalier Departemental Vendee, Dinoprostone (NCT02649920)
- 2024-08-14Results posted on the registry: Daniel Grossman, MD, Mifepristone (NCT03913104)
- 2024-07-31Results posted on the registry: Stanford University, Mifepristone + Misoprostol (NCT05097326)
- 2024-07-31Also stopped (withdrawn): Assiut University, Misoprostol + Isosorbide mononitrate (NCT02573051)
- 2024-07-19Results posted on the registry: Columbia University, Misoprostol (NCT03670836)
- 2024-07-03Results posted on the registry: University of Texas at Austin, 50 Micrograms Vaginal Misoprostol (Intervention) + 25 Micrograms Vaginal Misoprostol (Control) (NCT05262738)
- 2024-04-30Results posted on the registry: University of Pennsylvania, Misoprostol + Oxytocin (NCT04028765)
- 2024-03-22Phase 3 first posted: Cairo University, Misoprostol 200mcg Tab + Oxytocin (NCT06325501)
- 2024-02-14Phase 3 first posted: Icahn School of Medicine at Mount Sinai, Misoprostol + Pitocin (NCT06259097)
- 2024-01-09Results posted on the registry: Antonios Likourezos, Standard + Standard-vaginal misoprostol (NCT03815344)
- 2023-11-07Also stopped (terminated): MemorialCare Health System, Misoprostol (NCT00514618)
- 2023-10-30Also stopped (terminated): Bnai Zion Medical Center, Misoprostol Oral Tablet (NCT03866772)
- 2023-10-23Results posted on the registry: MemorialCare Health System, Misoprostol (NCT00514618)
- 2023-10-12Phase 3 first posted: Stanford University, Misoprostol 400mcg buccal + Placebo (NCT06078501)
- 2023-09-15Also stopped (suspended): Guangzhou Women and Children's Medical Center, Induction of labor with PGE2 (NCT04780269)
- 2023-09-07Results posted on the registry: Northwestern University, Misoprostol + Placebo (NCT02209545)
- 2023-09-07Also stopped (terminated): Northwestern University, Misoprostol + Placebo (NCT02209545)
- 2023-07-25Also stopped (terminated): Gynuity Health Projects, Mifepristone + 2 doses of misoprostol 800 mcg (NCT05119439)
- 2023-07-24Phase 3 first posted: Services Institute of Medical Sciences, Pakistan, Misoprostol Oral Tablet + vaginal misoprostol (NCT05957666)
- 2023-06-28Results posted on the registry: University of North Carolina, Chapel Hill, Ulipristal Acetate Tablets + Misoprostol Pill (NCT05216952)
- 2023-05-15Also stopped (terminated): University Hospital, Toulouse, Balloon catheter + oral misoprostol + Oral misoprostol alone (NCT03435458)
- 2023-05-03Phase 3 first posted: Planned Parenthood League of Massachusetts, Mifepristone plus one dose Misoprostol + Mifepristone plus two doses Misoprostol (NCT05839899)
- 2023-03-17Phase 3 first posted: Hospital Universitario 12 de Octubre, Vaginal dinoprostone (NCT05774236)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision